Asterias Biotherapeutics, Inc. (NYSEMKT:AST) Files An 8-K Results of Operations and Financial Condition


Asterias Biotherapeutics, Inc. (NYSEMKT:AST) Files An 8-K Results of Operations and Financial Condition

Item 2.02

Results of Operations and Financial Condition.

On November 14, 2016, Asterias Biotherapeutics, Inc. (the
Company) announced via press release certain operating and
financial results for the quarter ended September 30, 2016. A
copy of the Companys press release is attached hereto as Exhibit

Also on November 14, 2016, the Company held a conference call
with analysts and investors, the transcript is filed as Exhibit
99.2 hereto and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the
information in Item 2.02 of this Current Report on Form 8-K,
including Exhibits 99.1 and 99.2, shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the liability
of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific
reference in such a filing.

Item 9.01

Financial Tables and Exhibits.





Asterias Biotherapeutics, Inc. Press Release dated November
14, 2016.


Transcript of conference call held on November 14, 2016.

About Asterias Biotherapeutics, Inc. (NYSEMKT:AST)

Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Asterias Biotherapeutics, Inc. (NYSEMKT:AST) Recent Trading Information

Asterias Biotherapeutics, Inc. (NYSEMKT:AST) closed its last trading session up +0.40 at 4.80 with 153,947 shares trading hands.